Acquisition of resistance to anoikis (detachment-induced apoptosis) is considered to be a requirement for transformed intestinal epithelial cells to invade surrounding tissues and metastasize to distant organs. Increased Src kinase activity, which is a feature of a large proportion of colorectal cancers, has been identi®ed as one of the factors that can contribute to anoikis resistance. However, the molecular mechanism by which high levels of Src activity contribute to anoikis resistance in intestinal epithelial cells is unknown. Here we show that high Src activity confers resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x L overexpression, and that this induction is mediated by the MEK/MAPK pathway. Based on the ®ndings reported here, and on our previous study showing that Bcl-x L plays a critical role in ras-induced resistance to anoikis, we propose that the increased Bclx L levels found in colorectal cancers play a signi®cant role in the induction of resistance to anoikis during the progression of this disease.
Acquisition of resistance to anoikis (detachment-induced apoptosis) is considered to be a requirement for transformed intestinal epithelial cells to invade surrounding tissues and metastasize to distant organs. Increased Src kinase activity, which is a feature of a large proportion of colorectal cancers, has been identi®ed as one of the factors that can contribute to anoikis resistance. However, the molecular mechanism by which high levels of Src activity contribute to anoikis resistance in intestinal epithelial cells is unknown. Here we show that high Src activity confers resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x L overexpression, and that this induction is mediated by the MEK/MAPK pathway. Based on the ®ndings reported here, and on our previous study showing that Bcl-x L plays a critical role in ras-induced resistance to anoikis, we propose that the increased Bclx L levels found in colorectal cancers play a signi®cant role in the induction of resistance to anoikis during the progression of this disease. Oncogene (2002) 21, 2908 ± 2913. DOI: 10.1038/sj/ onc/1205388
Keywords: Bcl-x L ; v-Src; anoikis; intestinal epithelial cells Most types of normal epithelial cells undergo apoptosis when they are deprived of attachment to a type of extracellular matrix (ECM) called basement membrane, a phenomenon referred to as anoikis (Frisch and Francis, 1994 , Frisch and Ruoslahti, 1997 , Frisch and Screaton, 2001 Meredith et al., 1993, Meredith and Schwartz, 1997) . Intestinal epithelial cells are particularly sensitive to anoikis (Grossmann et al., 1998; Rak et al., 1995; Strater et al., 1996) . Cancer cells derived from the intestinal epithelium, on the other hand, are resistant to this form of cell death (Rak et al., 1995) , and it has been proposed that such resistance is essential for invasion and metastasis (Rosen et al., 1998 (Rosen et al., , 2000 .
What is the molecular basis for the resistance to anoikis found in intestinal tumors? Studies performed in our laboratory (Rosen et al., 1998 (Rosen et al., , 2000 indicate that one of the contributing factors in the development of resistance to anoikis is the activation of ras, an event that is frequent in colorectal cancer (Barbacid, 1987; Bos et al., 1987) . Furthermore, we showed that ras-induced resistance to anoikis in intestinal epithelial cells is mediated by at least two distinct mechanisms: one that involves downregulation of the pro-apoptotic molecule Bak (Rosen et al., 1998) , and another that stabilizes the expression of the anti-apoptotic protein Bcl-x L , which is otherwise downregulated in the absence of attachment to the ECM (Rosen et al., 2000) .
Another protein that has been associated with colorectal cancer progression and which has the potential to inhibit anoikis is c-Src (Biscardi et al., 1999; Irby and Yeatman, 2000) . c-Src is a non-receptor tyrosine kinase that plays a key role in the signal transduction pathways triggered by several growth factor receptors and adhesion molecules (Abram and Courtneige, 2000; Bjorge et al., 2001) . Alteration of cSrc activity, therefore, can have a profound impact on the regulation of cell proliferation and survival (Biscardi et al., 1999; Irby and Yeatman, 2000) , and mutations that increase Src activity can be oncogenic, as has been shown for v-Src (Hjelle et al., 1988) .
The correlation between colorectal cancer progression and augmented Src kinase activity is well documented (Cartwright et al., 1990; Talamonti et al., 1993) , with the highest levels of Src activity being found in metastatic lesions (Han et al., 1996; Talamonti et al., 1993) . Furthermore, several functional studies have established that increased Src activity can confer malignant properties to intestinal epithelial cells, suggesting that this kinase can play a causal role in colorectal tumor progression (Oldham et al., 1996; Pories et al., 1998; Staley et al., 1997) .
The mechanism by which Src activity is increased during the evolution of colorectal tumors is still controversial. Irby et al. (1999) have reported that activating c-Src mutations can be found in a proportion of colorectal tumors, but these results have not been reproduced by others (Daigo et al., 1999; Laghi et al., 2001) .
It is well established that increased Src activity can induce resistance to anoikis in several cell types, including intestinal epithelial cells (Frisch and Francis, 1994; Oldham et al., 1998) . However, the molecular mechanism underlying this phenomenon is unknown.
The purpose of this work is to identify such a mechanism.
In the present study we used IEC-18, a cell line derived from normal rat intestinal epithelium that is highly sensitive to anoikis, and which has been previously used to study the mechanisms of rasinduced resistance to anoikis (Rak et al., 1995; Rosen et al., 1998 Rosen et al., , 2000 . To investigate the eect of elevated Src activity on the sensitivity to anoikis of IEC-18 cells we used three independently-derived v-Src-transformed clones (named vSrc2, vSrc3 and vSrc4) (Jamal et al., 1994) .
First, we characterized the resistance to anoikis of these clones by comparing the levels of apoptosis of cells grown in monolayer to those cultured in suspension. As expected, we found that the three vSrc transformed clones display a strong resistance to anoikis ( Figure 1a ).
Since our previous studies had shown that rasinduced resistance to anoikis in the IEC-18 cells is mediated by the Bcl-2 family members Bak and Bcl-x L Figure 1 v-Src induces resistance to anoikis in IEC-18 cells. Cells were grown for 16 h in monolayer (mon) or suspension (sus) cultures as previously described (Jamal et al., 1994; Rosen et al., 1998) , and apoptosis was measured by using a Cell Death Elisa kit (Boehringer Mannheim). This kit assesses the amount of oligonucleosomes found in the cytoplasm, which is proportional to cell death, and is measured with a spectrophotometer (OD 405 nm ). Bars represent the average of duplicates (values diered less than 10% in all cases). A representative experiment out of three is shown. (b) v-Src induces Bcl-xL in IEC-18 cells. Top panel: cells were grown for 16 h in monolayer (mon) or suspension (sus) cultures, and Western blot analysis of Bcl-x L was performed as previously described (Rosen et al., 2000) , using an antibody from Transduction Laboratories (B22620). Bottom panel: The same blot was stripped and re-probed for CDK4 as a loading control. (c) v-Src-transfected clones display increased Bcl-xL mRNA levels. Top panel: Total RNA was extracted from cells growing as monolayers, and Northern blot analysis of Bcl-xL was performed as previously described (Rosen et al., 2000) . Bottom panel: Ethidium bromide staining of the ribosomal RNAs (28S and 18S) was used as a loading control (Rosen et al., 1998 (Rosen et al., , 2000 , the levels of expression of these two molecules in the parental IEC-18 cells and the v-Src-transformed clones were compared. No signi®cant dierences in Bak levels were observed (data not shown). Bcl-x L , on the other hand, was signi®cantly increased in the v-Src clones both in monolayer and suspension cultures (Figure 1b) . The amount of Bcl-x L mRNA was also signi®cantly higher in the v-Src clones (Figure 1c) .
To investigate whether the v-Src-induced upregulation of Bcl-x L plays a role in conferring resistance to anoikis to the v-Src-transformed clones, one of these clones (vSrc2) was transfected with a previously used anti-sense Bcl-x L cDNA expression vector (Rosen et al., 2000) . Three independent clones showing a signi®cant reduction of Bcl-x L expression were generated (Figure 2a) . To investigate whether the reduction of Bcl-x L expression has an impact on the sensitivity to anoikis, the three clones were plated in monolayer and suspension cultures and apoptosis was measured. As shown in Figure 2b , while in monolayer culture the three clones transfected with anti-sense Bcl-x L and control clones transfected with vector alone displayed low levels of apoptosis, in suspension culture the antisense clones showed signi®cantly higher levels of death, which re¯ects an increase in their sensitivity to anoikis. We conclude, therefore, that v-Src-induced resistance to anoikis in IEC-18 cells is caused, at least in part, by increased Bcl-x L expression.
The transforming activity of v-Src is mediated by several signaling molecules in a cell-type speci®c manner (Abram and Courtneidge, 2000; Odajima et al., 2000; Oldham et al., 1998; Penuel and Martin, 1999) . In the case of intestinal epithelial cells, a recent study showed that v-Src induces the activity of MEK and phosphatidylinositol 3-kinase (PI3K), and that the inhibition of these kinases strongly suppresses anchorage-independent growth of v-Src-transformed cells (Nguyen et al., 2000) . Although in that study the eect of MEK and PI3K inhibition on anoikis was not speci®cally investigated, we have previously shown that in intestinal epithelial cells the ability to grow in an anchorage-independent manner correlates with resistance to anoikis (Rosen et al., 1998 (Rosen et al., , 2000 . Since Bcl-x L mediates v-Src-induced resistance to anoikis in IEC-18 cells, we decided to investigate whether the upregulation of Bcl-x L induced by this oncogene is mediated by MEK and/or PI3K.
To study the role of the PI3K pathway, vSrc3 cells grown in monolayer or suspension culture were treated with the pharmacological PI3K inhibitor LY294002. Figure 3a shows that whereas phosphorylation at Ser473 of protein kinase B (PKB), a well established target of PI3K, was eciently inhibited We also investigated whether the simultaneous inhibition of PI3K and MEK pathways could have a more drastic suppressive eect on Bcl-x L expression than the inhibition of the MEK pathway alone. To this end, we treated the v-Src-transformed cells with PD98059 and LY294002 simultaneously. As shown in Figure 3b , the reduction on Bcl-x L expression generated by both drugs was similar to that observed after treatment with PD98059 only. This result provides additional support to the lack of involvement of the PI3K pathway in the induction of Bcl-x L expression by v-Src in IEC-18 cells. We also corroborated that both pharmacological inhibitors were acting in these cells according to their originally described speci®city. The results shown in Figure 3c demonstrate that, as expected, PD98059 does not inhibit PI3K, and that LY294002 does not act on MEK.
To con®rm the results obtained with the pharmacological inhibitor we decided to inhibit the MEK/ MAPK pathway by transfecting v-Src cells with a dominant negative mutant of MEK-1 (dnMEK-1) (Mansour et al., 1994) . As shown in Figure 3d , dnMEK-1 transfection induced a signi®cant reduction in the amount of phosphorylated MAPK. This was accompanied by a noticeable inhibition of Bcl-x L expression, con®rming the observations made with the pharmacological inhibitor of MEK.
v-Src is a strong inducer of phospho-ERK in suspended cells (Figure 4a ). We investigated, therefore, whether the v-Src-induced upregulation of Bcl-x L expression can also be inhibited by the suppression of the MEK/MAPK pathway in cells that are growing without attachment. Figure 4b shows that this is indeed the case, since treatment of v-Src cells grown in suspension with PD98059 signi®cantly suppressed Bcl-x L expression.
Since we have shown that the resistance to anoikis conferred to IEC-18 cells by v-Src is, at least in part, mediated by Bcl-x L , and that this induction requires MEK activity, it should be expected that MEK inhibition will make v-Src-transformed cells sensitive to anoikis. Figure 4c shows that this indeed is the case, since the treatment of v-Src-transformed cells with PD98059 restored sensitivity to anoikis, while it had a small eect on the survival of attached cells.
In conclusion, we have shown here that high levels of Src activity confer resistance to anoikis in intestinal epithelial cells, at least in part, by inducing Bcl-x L overexpression, and that this induction is mediated by the MEK/MAPK pathway. To induce high levels of Src activity in the intestinal epithelial cells we have ectopically expressed v-Src, a form of Src that is constitutively active. In addition, recent results obtained in our laboratory indicate that the induction of Bcl-x L expression in intestinal epithelial cells can also be achieved by stimulating endogenous c-Src activity with transforming growth factor a (TGF-a) (Rosen et al., 2001) . Moreover, other investigators have shown that endogenous c-Src activity can regulate Bcl-x L expression levels in ®broblasts (Karni et al., 1999) . Collectively these results indicate that the upregulation of Bcl-x L shown here is not unique to v-Src-induced transformation, but represents a more general eect of increased Src kinase activity.
Our ®nding that v-Src-induced upregulation of Bclx L is mediated by the MEK/MAPK pathway is consistent with a previous report showing that a MEK-dependent pathway regulates Bcl-x L expression in keratinocytes and mammary epithelial cells (Jost et al., 2001; Schulze et al., 2001) . In that report it was also shown that a dominant-negative MEK inhibits the transcriptional activity of the Bcl-x L promoter, but the precise mechanism by which MEK regulates such transcription remains to be identi®ed. Another signaling molecule that is known to mediate v-Src-induced transformation is the Signal Transducer and Activator of Transcription-3 (Stat3) (Bowman et al., 2000; Bromberg et al., 1998) . Moreover, in certain cell types Stat3 can directly activate Bcl-x L expression (Bromberg et al., 1998) . Thus at this point in time we cannot rule out a role for this molecule in the v-Src-induced upregulation of Bcl-x L expression in IEC-18 cells. In fact, it is now well established that the full oncogenic activities of v-Src are mediated by multiple pathways (Odajima et al., 2000; Penuel and Martin, 1999; Schwartzberg, 1998) and it is certainly conceivable that both MEK and Stat3 contribute to the induction of Bcl-x L expression in intestinal epithelial cells.
Although activated ras and Src have the capacity to inhibit anoikis of IEC-18 cells, these oncogenes seem to do so via distinct mechanisms. We have previously reported that detachment of intestinal epithelial cells induces the downregulation of Bcl-x L expression (Rosen et al., 2000) . Activated ras completely abrogates such downregulation, but, unlike v-Src, it does not signi®cantly upregulate Bcl-x L expression in monolayer culture (Rosen et al., 2000) . Another dierence that should be noted between the molecular mechanism by which v-Src and activated ras inhibit anoikis is that in ras-transformed cells the downregulation of Bak also contributes to anoikis resistance (Rosen et al., 1998) , whereas v-Src does not alter Bak expression signi®cantly (data not shown).
A large proportion of colorectal cancers express higher levels of Bcl-x L than the adjacent normal epithelium (Krajewska et al., 1996) . Based on the ®ndings reported here, and of our previous study showing that Bcl-x L plays a critical role in ras-induced resistance to anoikis (Rosen et al., 2000) , we propose that the increased expression of this anti-apoptotic molecule found in colorectal cancer plays a key role in the induction of resistance to anoikis during the progression of this disease.
